What is more effective for treating non-tubercular mycobacteria (NTM) infection of the gastrointestinal (GI) tract causing diarrhea, clarithromycin (Biaxin) or azithromycin (Zithromax)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For non-tubercular mycobacterial (NTM) infections of the GI tract causing diarrhea, clarithromycin is the preferred first agent, as it has been studied more extensively and appears to be associated with more rapid clearance of MAC from the blood 1. When considering treatment options, several factors come into play, including the potential for drug interactions, intolerance, and the efficacy of the medication against the specific NTM causing the infection.

  • The recommended regimen typically includes clarithromycin at a dose of 500 mg twice daily, usually combined with other antimycobacterial drugs to prevent or delay the emergence of resistance 1.
  • Azithromycin can be substituted for clarithromycin when drug interactions or clarithromycin intolerance preclude the use of clarithromycin 1.
  • Testing MAC isolates for susceptibility to clarithromycin or azithromycin is recommended for all patients to ensure the most effective treatment regimen 1.
  • It's essential to consider the potential side effects and drug interactions of the chosen regimen, as well as the need for regular monitoring to ensure the treatment's efficacy and safety.
  • The most common NTM causing GI infections is Mycobacterium avium complex (MAC), and clarithromycin has demonstrated excellent activity against these organisms 1.
  • Treatment should continue until symptoms resolve and cultures remain negative for at least 12 months, with regular monitoring for side effects and adjustments to the treatment regimen as needed.

From the Research

Comparison of Clarithromycin and Azithromycin

  • Both clarithromycin and azithromycin have been used to treat non-tuberculous mycobacterial (NTM) infections, including those causing diarrhea in the GI tract 2.
  • However, the choice between these two antibiotics depends on various factors, including the specific species of NTM, the severity of the infection, and the patient's overall health.

Efficacy of Clarithromycin and Azithromycin

  • Clarithromycin and azithromycin have been shown to be effective against several NTM species, including Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium genavense 2.
  • Azithromycin, in particular, has been used as part of a combination therapy regimen for the treatment of NTM infections, including those caused by Mycobacterium avium complex 3.

Treatment Challenges

  • NTM infections are often difficult to treat due to their intrinsic multidrug resistance and the limited efficacy of existing treatments 4, 3.
  • The treatment of NTM infections requires a prolonged course of antibiotics, which can be challenging for patients to tolerate 5, 6.
  • The development of new therapeutic strategies, including the use of alternative antibiotics and combination therapy regimens, is urgently needed to improve treatment outcomes for NTM infections 4, 3.

Specific Considerations for GI Tract Infections

  • The treatment of NTM infections in the GI tract, including those causing diarrhea, requires careful consideration of the specific species of NTM and the patient's overall health 6.
  • A combination therapy regimen that includes clarithromycin or azithromycin may be effective for the treatment of NTM infections in the GI tract, but the optimal treatment approach is not well established 2, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease.

Journal of clinical tuberculosis and other mycobacterial diseases, 2021

Research

Treatment of infections caused by nontuberculous mycobacteria.

Enfermedades infecciosas y microbiologia clinica (English ed.), 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.